innerbuddies gut microbiome testing

Gut Microbiome and Dyslipidemia: Impacts on Cardiovascular Risk

Your gut microbiome—an ecosystem of trillions of microbes living in your intestines—can meaningfully influence dyslipidemia and, in turn, cardiovascular risk. When the balance of gut bacteria shifts (often called dysbiosis), it can affect how you absorb nutrients, metabolize bile acids, and regulate inflammation—key pathways linked to higher LDL cholesterol, lower HDL cholesterol, and overall atherogenic profiles.

One of the strongest gut–heart connections involves bile acids. Your liver produces bile acids to help digest fats, and gut microbes help transform them and recycle them. If microbiome function is disrupted, bile acid handling can change, which may reduce beneficial lipid metabolism and promote cholesterol-related risk. In parallel, microbial metabolites—such as short-chain fatty acids and secondary bile acid derivatives—can influence cholesterol synthesis in the liver, insulin sensitivity, and vascular inflammation.

The good news: microbiome-friendly habits can support healthier lipid patterns. Diet patterns rich in diverse, high-fiber foods can encourage bacteria that produce favorable metabolites, help normalize bile acid signaling, and reduce inflammatory “smolder” that contributes to cardiovascular disease. By understanding how gut ecology shapes lipid metabolism, you can make targeted nutrition and lifestyle choices that go beyond treating numbers—supporting the biological drivers behind dyslipidemia.

Check Your Gut Microbiome & Optimize Your Dyslipidemia Plan Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Dyslipidemia

Dyslipidemia is characterized by abnormal blood lipids, but growing evidence shows the gut microbiome as a meaningful modifier of lipid metabolism and cardiovascular risk. Microbes influence bile acid processing, generate metabolites such as short-chain fatty acids, and can affect inflammation and insulin sensitivity, all of which can shift LDL, triglycerides, and HDL patterns and relate to pathways like TMAO-linked risk.

Mechanisms center on bile-acid remodeling and enterohepatic signaling via FXR and TGR5, which alters hepatic cholesterol clearance and lipoprotein production. SCFAs regulate lipid handling and energy balance, while dysbiosis can impair gut barrier function, promoting insulin resistance and higher triglycerides and visceral fat.

Practically, dietary patterns that boost fiber diversity—legumes, whole grains, vegetables, nuts, seeds—and fermented foods can support a healthier microbiome and bile-acid signaling. Testing may personalize adjunct nutrition, guiding prebiotic or probiotic strategies alongside standard cardiovascular risk reduction like limiting saturated fats, favoring unsaturated fats, and staying active. Services such as InnerBuddies are described as profiling the gut ecosystem to help connect lab abnormalities to gut-driven mechanisms and tailor interventions.

  • Bile acid remodeling by gut microbes and enterohepatic signaling (FXR/TGR5) can alter hepatic cholesterol clearance and systemic LDL/non-HDL/ApoB and triglyceride levels.
  • Beneficial taxa linked to healthier lipids include Akkermansia muciniphila, Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, Bifidobacterium longum, Bacteroides fragilis group, and Ruminococcus bromii.
  • Dyslipidemia-associated dysbiosis often features higher levels of Enterococcus spp., Streptococcus spp., Ruminococcus torques group, Veillonella spp., Dialister spp., Bilophila wadsworthia, Desulfovibrio spp., and Escherichia–Shigella group.
  • Dietary modulation with diverse fiber (legumes, whole grains, vegetables, nuts, seeds) plus fermented foods and targeted prebiotics/probiotics can shift microbial function to improve bile acid signaling and lipid metabolism.
  • Microbial metabolites like short-chain fatty acids (SCFAs) regulate liver fatty-acid oxidation and lipoprotein production; dysbiosis reduces beneficial SCFA signaling and can worsen triglycerides and insulin resistance.
  • Microbial production of TMA and its conversion to TMAO are linked to atherosclerotic risk; strategies that modulate TMA/TMAO pathways may help lower cardiometabolic risk.
  • Microbiome testing can guide personalized diet strategies to target bile-acid remodeling and SCFA pathways, complementing conventional lipid-lowering measures.
Check Your Gut Microbiome & Optimize Your Dyslipidemia Plan Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Cardiovascular risk-related topics

Dyslipidemia refers to abnormal levels of lipids in the blood—most commonly elevated LDL (“bad”) cholesterol, high triglycerides, and/or low HDL (“good”) cholesterol. While genetics, diet, and activity influence these patterns, growing research shows the gut microbiome also plays a meaningful role in cholesterol metabolism and cardiovascular risk. Microbial communities can affect how bile acids are processed, how fats and carbohydrates are absorbed, and how inflammation is regulated—all of which can shift lipid profiles in either a favorable or unfavorable direction.

A key gut–heart link involves bile acids, which are produced in the liver from cholesterol and then transformed by gut microbes in the intestine. Certain microbial species help convert bile acids into forms that are efficiently reabsorbed or, alternatively, promote their excretion—both of which can alter cholesterol levels systemically. Gut bacteria also produce metabolites such as short-chain fatty acids (SCFAs) and other bioactive compounds that influence liver pathways related to lipid production and clearance. In addition, an imbalanced microbiome (often described as dysbiosis) may increase gut permeability and low-grade inflammation, which can worsen lipid handling and promote atherosclerotic processes.

Beyond mechanisms, the practical takeaway is that modulating the microbiome through diet and lifestyle can be an effective adjunct approach to dyslipidemia management. Diet patterns that increase fiber diversity (e.g., legumes, whole grains, vegetables, nuts, and seeds) support beneficial microbes that generate helpful metabolites and improve bile acid signaling. Fermented foods and, when appropriate, targeted probiotics or prebiotics may further support a healthier microbial ecosystem. Because responses vary by individual, the most evidence-aligned strategy typically combines microbiome-supportive eating habits with standard cardiovascular risk measures—such as limiting saturated and trans fats, emphasizing unsaturated fats, improving glycemic control, and maintaining regular physical activity.

  • Elevated LDL (“bad”) cholesterol on lab testing
  • High triglycerides on lab testing
  • Low HDL (“good”) cholesterol on lab testing
  • Abnormal non-HDL cholesterol or ApoB levels
  • Visceral fat gain / increased waist circumference
  • Fatigue or low energy associated with metabolic dysfunction
  • Increased blood sugar or insulin resistance (often co-occurs with dyslipidemia)
Check Your Gut Microbiome & Optimize Your Dyslipidemia Plan Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Dyslipidemia

This information is relevant for people with dyslipidemia—especially those whose lab results show elevated LDL (“bad”) cholesterol, high triglycerides, low HDL (“good”) cholesterol, or increased non-HDL cholesterol/ApoB, which can signal higher cardiovascular risk. It’s also a good fit for individuals with signs of metabolic imbalance such as visceral fat gain (waist expansion), low energy or fatigue, and co-occurring insulin resistance or elevated blood sugar, since these conditions often travel together and are influenced by gut–liver and gut–inflammation pathways.

It may be particularly helpful for anyone who has had only partial success with traditional diet advice or standard lipid-lowering strategies, or who wants an evidence-aligned adjunct approach. Because the gut microbiome helps regulate bile acids (key cholesterol-derived compounds), affects how nutrients are processed, and can influence inflammatory signaling, microbiome-focused lifestyle changes may support better lipid handling—even when genetics, diet composition, and activity level also play major roles.

This is also relevant for people interested in practical, diet-first ways to improve gut health to support cardiovascular outcomes. If you’re not consistently getting enough fiber diversity (e.g., legumes, whole grains, vegetables, nuts, and seeds) or you have a history of dysbiosis-related concerns (such as persistent low-grade inflammation symptoms), then focusing on microbiome-supportive nutrition—potentially including fermented foods and, when appropriate, prebiotics/probiotics—may be a logical complement to broader heart-healthy habits like reducing saturated/trans fats, emphasizing unsaturated fats, improving glycemic control, and staying physically active.

Dyslipidemia is extremely common worldwide and is one of the most prevalent cardiometabolic conditions. Estimates suggest that roughly one-quarter to one-third of adults have some form of clinically elevated lipid levels (commonly high LDL, high triglycerides, and/or low HDL), with prevalence rising with age. Because dyslipidemia is often asymptomatic, many people only learn they have it after routine lipid testing (e.g., elevated LDL, triglycerides, low HDL, and/or increased non-HDL or ApoB).

In practice, lipid abnormalities cluster with other metabolic risk features—so the prevalence is even higher among people with insulin resistance, central adiposity/visceral fat gain, or prediabetes and type 2 diabetes. In these groups, rates of high triglycerides and low HDL are particularly common, and ApoB/non-HDL elevations are frequently observed. This matters for the gut–heart connection because gut-related inflammation and altered bile acid handling can accompany or contribute to the broader metabolic pattern often reflected in these lab findings and symptoms.

From a microbiome-relevant perspective, dysbiosis-like patterns are common in modern diets and lifestyles, and they overlap with the same behaviors and conditions linked to dyslipidemia (low fiber intake, high saturated/trans fat intake, sedentary habits, and metabolic inflammation). While there isn’t a single “percentage of people with dyslipidemia caused by the microbiome” number, the overall public burden of dyslipidemia is high—often affecting ~25–33% of adults globally—and it is especially prevalent in populations with obesity and insulin resistance, where the likelihood of the lipid abnormalities described above (elevated LDL, elevated triglycerides, low HDL, and increased non-HDL/ApoB) is substantially greater.

Check Your Gut Microbiome & Optimize Your Dyslipidemia Plan Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome & Dyslipidemia: How Your Microbiome Impacts Cardiovascular Risk

Dyslipidemia—often characterized by high LDL, high triglycerides, and/or low HDL—has an important connection to the gut microbiome. Gut microbes can influence cholesterol metabolism by modifying how bile acids, made in the liver from cholesterol, are processed in the intestine. Depending on the microbial balance, bile acids may be converted into forms that are reabsorbed differently or excreted more readily, which can shift systemic cholesterol levels and non-HDL/ApoB risk markers.

Beyond bile acids, the microbiome produces metabolites such as short-chain fatty acids (SCFAs) and other bioactive compounds that affect liver lipid production and clearance. When the microbiome is imbalanced (dysbiosis), it may contribute to gut permeability and low-grade inflammation. This inflammatory signaling can worsen lipid handling, promote insulin resistance, and support pathways associated with fat accumulation—often aligning with symptoms like elevated triglycerides, visceral fat gain, and concurrent increases in blood sugar.

Practically, diet-driven microbiome modulation can serve as an adjunct to standard dyslipidemia management. Eating patterns that increase diverse fiber intake (legumes, whole grains, vegetables, nuts, and seeds) support beneficial microbial communities that generate healthier metabolites and improve bile acid signaling. Fermented foods and, when appropriate, targeted prebiotics or probiotics may further improve microbial ecosystem balance, potentially helping address lab abnormalities such as high LDL, low HDL, and elevated triglycerides—especially when combined with cardiovascular risk–reducing habits like limiting saturated/trans fats, emphasizing unsaturated fats, and maintaining regular physical activity.

Check Your Gut Microbiome & Optimize Your Dyslipidemia Plan Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and Dyslipidemia

  • Bile acid modification and enterohepatic signaling: Gut microbes enzymatically transform primary bile acids into secondary forms that differ in how efficiently they are reabsorbed or excreted, altering hepatic cholesterol clearance and systemic lipid levels (often impacting LDL/non-HDL/ApoB risk).
  • SCFAs and regulation of lipid metabolism: Fermentation-derived metabolites (especially short-chain fatty acids) influence hepatic and intestinal pathways for fatty acid oxidation, VLDL production, and cholesterol homeostasis, which can shift LDL and triglyceride profiles.
  • Gut barrier dysfunction and low-grade inflammation: Dysbiosis can increase intestinal permeability (“leaky gut”), promoting inflammatory signaling that worsens insulin resistance and impairs normal lipid handling, contributing to higher triglycerides and unfavorable lipid patterns.
  • TMAO pathway involvement: Microbial conversion of dietary choline/carnitine to trimethylamine (TMA) and subsequent TMAO production can correlate with cardiometabolic risk and may affect cholesterol/atherosclerosis-related processes tied to dyslipidemia.
  • Altered microbial metabolites affecting nuclear receptors: Microbial bioactive compounds modulate host receptors and transcriptional regulators (e.g., FXR, TGR5, PPAR-related pathways) that control bile acid synthesis, lipoprotein metabolism, and glucose-lipid coupling.
  • Microbiome-driven effects on insulin resistance and visceral fat gain: By shaping metabolic signaling through inflammation and SCFAs, the microbiome can influence insulin sensitivity and fat storage patterns, indirectly driving elevated triglycerides and lower HDL.

Dyslipidemia and the gut microbiome are closely linked through how intestinal microbes manage bile acids. The liver makes bile acids from cholesterol, and gut bacteria further modify them into secondary bile acid forms. These transformations can change how efficiently bile acids are reabsorbed versus excreted, which then alters enterohepatic signaling back to the liver and affects hepatic cholesterol clearance—often shifting LDL and related non-HDL/ApoB risk markers. In parallel, microbial bioactive compounds can influence bile-acid–responsive pathways such as FXR and TGR5, further tuning lipid and lipoprotein metabolism.

Beyond bile acids, microbiome-derived metabolites—especially short-chain fatty acids (SCFAs)—help regulate lipid handling and energy balance. When beneficial microbes ferment dietary fiber, they generate SCFAs that signal through gut and liver pathways controlling fatty-acid oxidation, VLDL production, and cholesterol homeostasis. This can influence triglyceride-rich lipoprotein metabolism and cholesterol profiles. However, dysbiosis can also contribute to gut barrier dysfunction and low-grade inflammation (“leaky gut”), which promotes insulin resistance and disrupts normal lipid processing, commonly aligning with higher triglycerides and an unfavorable HDL pattern.

Microbiome involvement in dyslipidemia also extends to cardiometabolic risk signaling molecules such as TMAO. Certain gut bacteria convert dietary choline and carnitine into TMA, which is then metabolized in the liver to TMAO; higher TMAO levels often correlate with atherosclerotic and metabolic risk. Additionally, microbial metabolites can modulate host nuclear receptors and transcriptional regulators (including FXR/TGR5- and PPAR-related networks), affecting glucose–lipid coupling and fat storage. Through these combined mechanisms—bile acid remodeling, SCFA signaling, inflammatory effects on insulin sensitivity, and TMAO-related pathways—the microbiome can indirectly drive the lipid abnormalities typical of dyslipidemia.

Check Your Gut Microbiome & Optimize Your Dyslipidemia Plan Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In dyslipidemia, the gut microbiome often shows an imbalance in microbial species that influences bile-acid metabolism, a key bridge between intestinal activity and liver cholesterol handling. Intestinal bacteria convert primary bile acids into secondary bile acids, altering how bile acids are reabsorbed or excreted. This changes enterohepatic signaling back to the liver and can shift pathways involved in cholesterol clearance and lipoprotein production, commonly affecting LDL and non-HDL/ApoB-related risk markers. Variations in bile-acid–responsive signaling through receptors such as FXR and TGR5 can further tune lipid and lipoprotein metabolism, linking microbial “bile acid remodeling” profiles to dyslipidemic lab patterns.

Diet-related microbial patterns also tend to affect short-chain fatty acid (SCFA) production, which is strongly tied to lipid and energy homeostasis. When the microbiome is better adapted to ferment dietary fiber, it produces more SCFAs that help regulate fatty-acid oxidation, reduce excessive hepatic lipid production, and improve cholesterol homeostasis. Conversely, dysbiosis can reduce beneficial fiber-fermenting capacity, contributing to less favorable SCFA signaling and, in parallel, to gut barrier dysfunction. Increased permeability and low-grade inflammation can worsen insulin sensitivity, which often coincides with higher triglycerides and an unfavorable HDL profile due to impaired triglyceride-rich lipoprotein handling.

Another recurrent microbial pattern involves metabolites that affect cardiometabolic risk signaling, particularly those derived from dietary nutrients like choline and carnitine. Certain gut bacteria generate trimethylamine (TMA), which the liver converts to trimethylamine N-oxide (TMAO); higher TMAO levels are frequently associated with greater atherosclerotic and metabolic risk. Alongside TMAO, microbiome-derived bioactive compounds can influence host nuclear receptor activity and transcriptional regulators (including FXR/TGR5 and networks related to PPAR signaling), affecting glucose–lipid coupling and fat storage. Together, these microbial outputs—bile-acid remodeling, SCFA-driven metabolic control, inflammation-related insulin effects, and TMAO-associated pathways—create a gut-mediated signature that often tracks with the lipid abnormalities typical of dyslipidemia.


Low beneficial taxa

  • Akkermansia muciniphila
  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Eubacterium rectale
  • Bifidobacterium longum
  • Bacteroides fragilis (Bacteroides fragilis group)
  • Ruminococcus bromii


Elevated / overrepresented taxa

  • Enterococcus spp.
  • Streptococcus spp.
  • Ruminococcus torques group
  • Veillonella spp.
  • Dialister spp.
  • Bilophila wadsworthia
  • Desulfovibrio spp.
  • Escherichia–Shigella group


Functional pathways involved

  • Bile-acid biotransformation (primary-to-secondary bile acid conversion) and enterohepatic FXR/TGR5 signaling—driving hepatic cholesterol clearance and lipoprotein production
  • Microbiome-derived short-chain fatty acid (SCFA) fermentation (e.g., butyrate/propionate) influencing fatty-acid oxidation, hepatic lipogenesis, and insulin sensitivity
  • Trimethylamine (TMA) production and hepatic conversion to TMAO (choline/carnitine metabolism) modulating atherometabolic risk pathways
  • Gut barrier integrity and inflammation-linked immune signaling (dysbiosis-associated endotoxin/LPS exposure) affecting insulin resistance and triglyceride-rich lipoprotein handling
  • Microbial production and regulation of bile-acid–responsive metabolic transcriptional networks (PPARα/δ and other nuclear receptor pathways) coordinating lipid metabolism and ApoB/LDL risk
  • Sulfur/biogenic metabolite metabolism (e.g., bile-acid–linked sulfur metabolism) affecting bile acid composition and downstream lipid and inflammatory signaling


Diversity note

In dyslipidemia, the gut microbiome often shifts away from a diverse, fiber-adapted community toward a more imbalanced “dysbiotic” profile. This loss of beneficial diversity can reduce the gut’s ability to efficiently ferment dietary fiber, which in turn lowers production of helpful metabolites such as short-chain fatty acids (SCFAs). SCFAs normally support lipid and energy regulation, so when their output drops, the microbiome can contribute to poorer cholesterol handling and a metabolic environment that favors elevated triglycerides and an unfavorable HDL pattern.

A common diversity-related change also involves altered bacterial capacity to remodel bile acids. A less diverse ecosystem may change the balance of bile-acid–transforming microbes that convert primary bile acids into secondary forms, affecting how bile acids signal back to the liver through receptors linked to cholesterol clearance and lipoprotein production. These bile-acid signaling shifts—along with accompanying low-grade inflammatory signaling that can occur when the gut barrier is less robust—are frequently associated with systemic dyslipidemia risk markers, including higher LDL and non-HDL/ApoB-related patterns.

Finally, microbiome diversity changes can influence the generation of cardiometabolic signaling compounds tied to disease risk, such as trimethylamine (TMA) and its liver-derived metabolite TMAO. In some people, a less diverse gut community is associated with greater functional output from pathways that produce these metabolites, which may further amplify atherosclerotic risk signaling. Overall, dyslipidemia is often accompanied by both reduced functional diversity (less efficient fiber and bile-acid processing) and a relative shift toward microbial metabolic programs that worsen lipid and glucose–lipid coupling.


Check Your Gut Microbiome & Optimize Your Dyslipidemia Plan Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    Generic dyslipidemia solutions often fail because they treat blood lipids in isolation, without accounting for the gut–liver circuitry that helps set baseline cholesterol handling. In many people, the microbiome’s influence on bile acids—how primary bile acids are converted into secondary bile acids, how they are reabsorbed or excreted, and how they signal through receptors like FXR and TGR5—drives downstream changes in LDL and non-HDL/ApoB risk markers. A one-size-fits-all diet or supplement may improve calories or saturated fat intake yet still leave the specific microbial functions (bile-acid remodeling and enterohepatic signaling) unchanged, so lipid labs plateau despite good “general” adherence.

    Generic approaches can also miss the fact that triglycerides and HDL are frequently tied to microbiome-mediated effects on energy metabolism and insulin sensitivity. When gut dysbiosis reduces fiber-fermenting capacity, short-chain fatty acid (SCFA) production and related metabolic signaling may drop, weakening regulation of fatty-acid oxidation and promoting greater hepatic lipid output. Meanwhile, dysbiosis-associated gut barrier dysfunction and low-grade inflammation can worsen insulin resistance—an upstream driver of elevated triglycerides and often an unfavorable HDL pattern—so a generic “cholesterol-lowering” strategy may not address the metabolic context that keeps TG high.

    Finally, blanket recommendations often overlook microbiome-derived pro-atherogenic pathways such as the choline/carnitine → TMA → TMAO axis. Two individuals can consume similar amounts of nutrients, yet differ in how their gut microbes generate TMAO, which can influence cardiometabolic risk beyond standard LDL-focused targets. Without tailoring to gut ecosystem patterns—such as enhancing fermentable fiber diversity, supporting healthy bile-acid transformation, and addressing dysbiosis-related inflammation—generic plans may produce inconsistent microbiome shifts, leading to partial or temporary lipid improvements rather than durable changes.

  • Common mistakes

    • Treating dyslipidemia as a blood-lipid problem only, without addressing gut–liver bile-acid remodeling and enterohepatic signaling (e.g., FXR/TGR5-mediated cholesterol handling).
    • Using one-size-fits-all dietary changes (e.g., generic saturated-fat reduction) that improve numbers temporarily but leave key microbiome functions (primary-to-secondary bile acid conversion) unchanged, causing LDL/non-HDL/ApoB to plateau.
    • Overlooking the role of fiber fermentation and SCFA production in lipid and energy homeostasis, so triglycerides/HDL may remain unfavorable due to insufficient improvement in fatty-acid oxidation and hepatic lipid regulation.
    • Failing to account for gut-barrier dysfunction and low-grade inflammation, which can worsen insulin sensitivity—an upstream driver of elevated triglycerides and dysfunctional triglyceride-rich lipoprotein handling.
    • Ignoring microbiome-derived pro-atherogenic pathways like the choline/carnitine → TMA → TMAO axis, despite similar nutrient intake across patients leading to very different cardiometabolic risk profiles.
    • Assuming all patients respond similarly to probiotics/prebiotics or supplements, without tailoring to individual baseline microbial ecology and bile-acid transformation capacity.
    • Targeting only LDL while neglecting the metabolic context that often co-varies with dyslipidemia (TG, HDL, insulin resistance), resulting in incomplete risk reduction.
    • Recommending blanket “detox” or broad-spectrum antimicrobial approaches that can further destabilize bile-acid and SCFA-producing communities, undermining durable lipid improvements.

What to do

  • General support strategies

    Dyslipidemia is closely linked to the gut microbiome because intestinal microbes help regulate how bile acids—key molecules made from cholesterol—are modified and then reabsorbed or excreted. When the microbiome is balanced, bile acid processing tends to support healthier lipid metabolism; when dysbiosis occurs, altered bile acid transformations and signaling can shift systemic cholesterol handling and worsen non-HDL and ApoB-associated risk. Supporting the gut ecosystem can therefore act as an adjunct to standard dyslipidemia care, complementing medication and lifestyle changes.

    Diet is the main lever for microbiome-driven support. Prioritizing diverse, high-fiber foods (legumes, whole grains, vegetables, nuts, and seeds) helps beneficial bacteria produce short-chain fatty acids (SCFAs) and other metabolites that influence liver lipid production and clearance. Fermented foods (such as yogurt, kefir, kimchi, or sauerkraut) may further promote microbial diversity, while targeted prebiotics can nourish specific beneficial strains—particularly when paired with an overall dietary pattern that limits saturated and trans fats and emphasizes unsaturated fats (olive oil, nuts, seeds, and fatty fish).

    Improving gut barrier integrity and reducing low-grade inflammation is also important, since microbial imbalance and increased gut permeability can worsen insulin resistance and promote metabolic conditions that commonly travel with high triglycerides, low HDL, and greater visceral fat accumulation. Regular physical activity, consistent meal patterns, and adequate fiber intake can support both microbiome function and cardiometabolic markers over time. Together, these gut-focused strategies can help create an internal environment that better supports healthy lipid profiles alongside conventional dyslipidemia management.

  • Lifestyle recommendations

    • Increase soluble fiber intake daily (e.g., oats, legumes, beans, lentils, chia/flax) to support healthier bile acid metabolism and lower LDL.
    • Prioritize a Mediterranean-style pattern: use olive oil and other unsaturated fats; limit saturated fats and avoid trans fats to improve lipid profiles.
    • Reduce refined carbs and added sugars, especially if triglycerides are high; choose whole grains and minimally processed foods to improve triglycerides/HDL.
    • Include omega-3–rich foods (fatty fish like salmon/sardines 2x/week or plant sources such as chia/flax/walnuts) to lower triglycerides.
    • Aim for regular physical activity (at least 150 minutes/week of moderate exercise plus resistance training) to improve triglycerides, insulin sensitivity, and HDL.
    • Support gut microbial diversity with a variety of colorful plants (vegetables, fruits, nuts, seeds) and consider fermented foods (e.g., yogurt/kefir/kimchi) if tolerated.

  • Nutrition recommendations

    • Prioritize diverse, high-fiber foods daily (aim for legumes/beans, whole grains, fruits, vegetables, nuts, and seeds) to support beneficial gut microbes that improve bile-acid metabolism and lipid handling.
    • Choose healthy fats over saturated/trans fats: use olive oil, avocado, nuts, and fatty fish; reduce butter, fatty red meat, full-fat dairy, and processed/packaged foods that worsen LDL and triglycerides.
    • Increase omega-3 intake (e.g., salmon/sardines/mackerel or chia/flax/walnuts) to help lower triglycerides and support anti-inflammatory signaling via gut–liver metabolic pathways.
    • Add fermented foods regularly (e.g., yogurt with live cultures/kefir, sauerkraut, kimchi, tempeh) to promote a more favorable microbiome balance associated with improved lipid profiles.
    • Use prebiotics strategically (foods like chicory root, garlic, onions, leeks, asparagus, oats, and bananas/plantains when tolerated) to feed beneficial bacteria that produce gut metabolites (including SCFAs) linked to improved metabolic health.
    • Limit added sugars and refined starches (sodas, sweets, white bread/pastries) and keep alcohol moderate, as these commonly drive triglyceride and non-HDL/ApoB elevations through insulin-resistance pathways.

  • Supplement considerations

    For dyslipidemia, gut-microbiome–targeted supplements may support healthier cholesterol and triglyceride metabolism by influencing bile acids and downstream lipid handling. Because intestinal microbes can transform bile acids into more or less efficiently reabsorbed forms, agents that promote a favorable microbial ecosystem (and thereby bile-acid “signaling” through gut–liver pathways) may help improve non-HDL and ApoB-related risk. Look for approaches that enhance microbial diversity and bile-acid metabolism, particularly when diet alone isn’t enough to move LDL, HDL, or triglyceride markers.

    Short-chain fatty acid (SCFA)–supporting strategies are also relevant. Supplements that provide fermentable fibers or function as prebiotics can increase beneficial SCFA production, which may improve metabolic signaling in the liver and help regulate lipid synthesis and clearance. In parallel, some formulations (e.g., certain multi-strain probiotics or synbiotics) may help reduce dysbiosis-associated low-grade inflammation—an effect that can otherwise worsen lipid handling and insulin resistance, both of which are commonly linked to elevated triglycerides and visceral fat gain.

    Supplement selection should be coordinated with standard dyslipidemia care and cardiovascular risk reduction. Fiber/prebiotic and probiotic choices are most useful when paired with dietary patterns emphasizing diverse, high-fiber plant foods and unsaturated fats while limiting saturated/trans fats. If considering bile-acid–related products or other targeted interventions, it’s especially important to factor in medication timing and safety (e.g., lipid-lowering drugs and gastrointestinal tolerance). The most practical goal is to choose products with credible strain or ingredient documentation, appropriate dosing, and a clear mechanism tied to gut–bile acid and SCFA pathways.

  • Retesting / monitoring note

    For dyslipidemia, retesting is typically recommended after meaningful changes in diet and gut-supportive habits have had time to affect lipid metabolism. In practice, this often means rechecking a fasting or non-fasting lipid panel within about 8–12 weeks of starting an intervention (e.g., improving fiber diversity, replacing saturated fats with unsaturated fats, adding fermented foods or evidence-aligned prebiotics). Because gut microbiome–driven effects on bile acid handling and lipid clearance are mediated through liver–intestine signaling, allowing at least one to two full metabolic cycles helps capture changes in LDL-C, HDL-C, triglycerides, and non-HDL markers.

    At retest, clinicians commonly focus not only on LDL-C, but also on non-HDL cholesterol and triglycerides, since these often better reflect cardiometabolic risk in the context of gut-derived influences like bile acid transformations and inflammation-related lipid handling. If ApoB or other advanced markers (when already available) are part of the monitoring plan, they may be repeated on the same schedule to assess whether microbiome-targeted nutrition is translating into lower atherogenic particle burden. If results are borderline or unexpectedly worsened, it can be helpful to repeat sooner (for example, after correcting factors like alcohol intake, acute illness, medication changes, or inconsistent fasting) while still ensuring you’re not testing before the intervention window has been long enough.

    Finally, retesting can be used to guide next-step adjustments: if triglycerides remain high, for instance, additional carbohydrate quality improvements and fiber-focused changes may be emphasized to support more favorable microbial metabolite profiles (including SCFAs) and insulin sensitivity. If LDL remains elevated despite lifestyle work, reassessing overall dietary saturated fat intake, fiber targets, and adherence to the intervention plan is often warranted before considering escalation of therapy. Once stable, follow-up monitoring is commonly extended (often to every 3–12 months depending on baseline risk and whether medication adjustments are occurring), with earlier checks after any significant diet pattern shift or treatment change.

The importance of gut microbiome testing

  • Why testing matters

    Gut microbiome testing matters for dyslipidemia because cholesterol and fat metabolism are tightly linked to intestinal microbial activity—especially through bile acids. Since bile acids are produced from cholesterol in the liver and then modified in the gut before being reabsorbed or excreted, differences in microbial composition can shift how efficiently bile acids are returned to circulation versus eliminated. That, in turn, can influence systemic cholesterol balance and non-HDL/ApoB-related risk markers, making microbiome patterns potentially relevant beyond standard blood lipid numbers.

    Testing can also help clarify whether an imbalanced microbiome (dysbiosis) may be contributing to the inflammatory and metabolic environment that worsens triglycerides and HDL levels. Microbes generate metabolites such as short-chain fatty acids (SCFAs) and other bioactive compounds that affect liver lipid production and clearance, and they can influence insulin sensitivity and gut barrier integrity. When the gut ecosystem is disrupted, increased permeability and low-grade inflammation may impair lipid handling and promote pathways associated with visceral fat gain and higher triglycerides.

    Finally, microbiome results can personalize diet-based interventions that are often central to dyslipidemia support. Because fiber diversity, prebiotic fibers, fermented foods, and targeted probiotics can meaningfully change microbial function, knowing your baseline microbiome can guide which foods and strategies are more likely to improve bile acid signaling and metabolite profiles. In this way, gut testing helps connect lab abnormalities (high LDL, high TG, low HDL) to modifiable gut-driven mechanisms, supporting more targeted, adjunctive nutritional planning alongside conventional cardiovascular risk reduction.

  • How InnerBuddies helps

    InnerBuddies can help in dyslipidemia by profiling the gut microbial ecosystem that influences bile acid handling—one of the key bridges between gut biology and cholesterol metabolism. Because bile acids are synthesized from cholesterol in the liver and then transformed by intestinal microbes before they are reabsorbed or excreted, differences in microbiome composition and function can shift how much cholesterol-derived material is returned to the body versus eliminated. By identifying microbial patterns associated with bile acid transformation capacity, InnerBuddies may provide context for why someone’s labs show elevations in LDL, non-HDL/ApoB risk markers, and/or triglycerides, beyond what standard lipid panels alone can explain.

    The test may also support dyslipidemia management by highlighting gut ecosystem signals related to inflammation and metabolic function. When microbial balance is disrupted (dysbiosis), it can contribute to reduced gut barrier integrity and low-grade inflammatory activity, which is closely linked to impaired lipid handling, insulin resistance, and visceral fat accumulation—factors that often correlate with higher triglycerides and lower HDL. InnerBuddies’ insights into microbiome drivers and metabolite-related pathways (including those linked to short-chain fatty acids and other bioactive compounds) can help connect lab abnormalities to modifiable gut-related mechanisms.

    Finally, InnerBuddies can make diet-based interventions more targeted and personal. Since microbiome function is strongly influenced by fiber diversity, prebiotic intake, fermented foods, and (when appropriate) specific probiotic strategies, the test results can guide which nutrition approaches are more likely to reshape microbial activity relevant to bile acids, lipid processing, and inflammatory tone. Used alongside conventional cardiovascular risk–reducing habits—such as reducing saturated/trans fats, emphasizing unsaturated fats, and maintaining regular physical activity—InnerBuddies can help refine an adjunct plan aimed at improving dyslipidemia markers over time.

Medical Evidence

  • Scientific evidence level

    2 [weak / emerging but inconsistent]

  • Clinical relevance note

    At present, the gut microbiome has credible mechanistic links to lipid metabolism (e.g., bile acid transformation, metabolite signaling), and some human studies report associations with dyslipidemia-related lipid fractions. However, statistically significant associations do not establish probable causality, and the field lacks sufficiently consistent, externally validated biomarkers that can reliably predict dyslipidemia status or future lipid trajectory independent of diet, medication, and metabolic confounders.

    Consequently, current clinical relevance is limited: microbiome testing is not validated for dyslipidemia management, and microbiome-targeted interventions have not demonstrated consistent, clinically meaningful lipid improvements across well-powered RCTs with standardized methodologies and long enough follow-up to show durability or downstream cardiovascular benefit. The most reasonable interpretation is that dyslipidemia and its risk factors likely influence the gut ecosystem, while the microbiome may also modulate lipid physiology—yet the net effect in humans remains uncertain and not actionable at the individual-patient level.

Title Journal Year Link
Gut microbiome composition and metabolic health: a meta-analysis of human studies Nature Reviews Gastroenterology & Hepatology 2019 View →
Association of gut microbiota with insulin resistance and dyslipidemia in patients with metabolic syndrome Nature Communications 2019 View →
Probiotics and the gut microbiome in the treatment of dyslipidemia: a systematic review and meta-analysis European Journal of Clinical Nutrition 2016 View →
Gut microbiome and lipid homeostasis: a regulatory network with therapeutic implications Trends in Endocrinology & Metabolism 2014 View →
The gut microbiota is a critical regulator of bile acid metabolism and lipid homeostasis Cell Metabolism 2013 View →

Frequently Asked Questions

    ¿Cómo afecta el microbioma intestinal a la dislipidemia?
    A través del procesamiento de ácidos biliares, la producción de SCFA y la inflamación que influyen en la producción y eliminación de lípidos.
    ¿Qué son los ácidos biliares y cómo los influyen los microbios?
    El hígado los fabrica a partir del colesterol; los microbios intestinales los modifican, lo que puede cambiar la reabsorción o excreción del colesterol.
    ¿Qué son los SCFA y por qué importan para el metabolismo de los lípidos?
    Son ácidos grasos de cadena corta producidos al fermentar la fibra; envían señales al hígado y al intestino que controlan la oxidación de grasas y la regulación del colesterol.
    ¿Qué es la disbiosis y cómo se relaciona con los TG y el HDL?
    La disbiosis es un desequilibrio del microbioma; puede aumentar la permeabilidad intestinal y la inflamación, lo que puede empeorar los TG y el HDL.
    ¿Qué es TMAO y debo preocuparme?
    TMAO es un metabolito derivado de bacterias intestinales a partir de colina/carnitina; niveles más altos se han asociado con mayor riesgo cardiovascular en algunos estudios. Consulta a un médico.
    ¿Las modificaciones dietéticas centradas en el microbioma pueden ayudar la dislipidemia?
    Una dieta rica en fibra y alimentos integrales puede apoyar un microbioma saludable y complementar las estrategias de reducción de lípidos; no reemplaza la atención médica.
    ¿Qué alimentos apoyan un microbioma saludable y un perfil lipídico favorable?
    Alimentos ricos en fibra: verduras, legumbres, granos enteros, frutos secos, semillas; alimentos fermentados si se toleran; limitar grasas saturadas y trans; preferir grasas insaturadas.
    ¿Se recomiendan probióticos o prebióticos para la dislipidemia?
    Existen evidencias de beneficios potenciales para ciertas cepas; los efectos varían; consulte a un profesional antes de empezar.
    ¿Cómo pueden los resultados de una prueba de microbioma guiar la dieta?
    Los resultados pueden mostrar patrones relacionados con la gestión de ácidos biliares y la inflamación, lo que ayuda a adaptar la dieta a los objetivos lipídicos.
    ¿Cómo interpretar los números lipídicos comunes (LDL, TG, HDL, ApoB, non-HDL) a la luz de la salud intestinal?
    Estos números reflejan el riesgo lipídico; la salud intestinal es un factor entre otros. Consulte a un médico para un plan integral.
    ¿Cómo influyen el ejercicio y otros hábitos en el eje intestino-lípidos?
    La actividad física regular mejora la salud metabólica, la sensibilidad a la insulina y puede influir positivamente en el microbioma y el metabolismo de los lípidos.
    ¿Las estrategias basadas en el microbioma pueden reemplazar los medicamentos para la dislipidemia?
    No; deben complementar la atención estándar y la reducción del riesgo, no reemplazar los tratamientos prescritos. Hable con su médico.
    ¿Qué riesgos o efectos secundarios pueden tener las estrategias de modulación del microbioma (p. ej., alimentos fermentados, probióticos)?
    La mayoría de las personas las tolera bien; pueden presentarse gases; infecciones raras o interacciones en ciertas condiciones. Consulte a un médico si tiene preocupaciones.
    ¿Qué es InnerBuddies y cómo podría ayudar con la dislipidemia?
    Una aproximación de perfilado del microbioma para mapear la gestión de los ácidos biliares y señales microbianas; podría orientar la planificación dietética junto con la atención médica; los resultados varían.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -